QGEN vs ILMN vs TECH Stock Comparison

Qiagen, Illumina and Bio-Techne Prices as of Nov 13, 2026 Peers: Industry group
1 more company in this comparison (DHR) Create a free account to keep reading and compare up to 10 companies.
QGEN Qiagen N.V.
$49.90 +9.6% 1M +6.2% 1Y
Market cap
$10.82B
P/E
28.1x
Revenue (TTM)
$2.12B
Div. yield
–
Life Sciences Tools Healthcare
4 wins
ILMN Illumina, Inc.
$207.01 -23.8% 1M +72.6% 1Y
Market cap
$29.98B
P/E
33.5x
Revenue (TTM)
$4.54B
Div. yield
–
Life Sciences Tools Healthcare
6 wins
TECH BIO-TECHNE Corp
$72.80 +0.4% 1M +19.8% 1Y
Market cap
$11.41B
P/E
66.4x
Revenue (TTM)
$1.23B
Div. yield
0.00%
Life Sciences Tools Healthcare
1 win

Head to Head

11 decided of 12

Illumina leads on 6 of the 12 questions below (Illumina 6, Qiagen 4, Bio-Techne 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionQGENILMNTECHLeader
Larger companyMarket capitalisation $10.82B $29.98B $11.41B ILMN
Cheaper on earningsLower P/E, profitable companies only 28.1x 33.5x 66.4x QGEN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.2x 40.9x 33.4x QGEN
Faster revenue growthRevenue growth, trailing twelve months +2.2% +5.8% +0.9% ILMN
More profitableNet margin, trailing twelve months 18.2% 19.7% 14.0% ILMN
Better return on capitalReturn on invested capital 7.4% 16.6% 7.8% ILMN
Less leveragedLower net debt / EBITDA 1.2x 0.4x -0.4x TECH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +6.2% +72.6% +19.8% ILMN
Better 5-year returnAnnualised price return, 5 years -3.6%/yr -11.1%/yr -10.4%/yr QGEN
Less volatileAnnualised volatility, 1 year 35.2% 51.1% 42.8% QGEN
Higher overall scoreMean of the five percentile scores vs peers 69/100 75/100 68/100 ILMN

Percentile Scorecard

QGENILMNTECH

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisQGENILMNTECH
Valuation 74 #63 of 243 63 #91 of 243 62 #92 of 243
Growth 25 #171 of 228 73 #63 of 228 56 #102 of 228
Profitability 93 #16 of 222 98 #5 of 222 94 #15 of 222
Financial Health 60 #100 of 248 57 #107 of 248 79 #53 of 248
Shareholder Returns 94 #11 of 158 85 #25 of 158 47 #84 of 158
Overall 69 75 68
  • QGEN ranked among 252 companies in Medical Devices and Diagnostics
  • ILMN ranked among 252 companies in Medical Devices and Diagnostics
  • TECH ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodQGENILMNTECHSPY
1 month +9.6%-23.8%+0.4% -2.0%
3 months +16.2%+8.4%+0.6% -2.8%
6 months +51.3%+45.2%+68.1% +2.0%
Year to date +5.4%+57.8%+23.8% +10.6%
1 year +6.2%+72.6%+19.8% +12.2%
3 years +13.0%+118.3%+20.6% +68.1%
3 years, per year +4.2%+29.7%+6.5% +18.9%
5 years -16.9%-44.5%-42.3% +61.4%
5 years, per year -3.6%-11.1%-10.4% +10.1%
10 years +56.5%+54.5%+173.4% +248.5%
10 years, per year +4.6%+4.4%+10.6% +13.3%

Risk

MeasureQGENILMNTECHSPY
Volatility, 1Y 35.2%51.1%42.8% 13.6%
Downside volatility, 1Y 29.7%50.9%43.2% 13.9%
Beta vs S&P 500, 1Y 0.381.110.63 1.00
Return / volatility, 1Y 0.181.420.46 0.90
Max drawdown, 5Y -48.2%-82.9%-66.5% -25.4%
From 52-week high -10.3%-29.5%-0.1% -3.2%
52-week high $55.66$293.69$72.84 $779.14
52-week low $32.63$114.44$43.30 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleQGENILMNTECH
P/E now vs peer median 28.2xmedian 26.5x 34.9xmedian 26.5x 66.4xmedian 26.5x
P/S now vs peer median 5.1xmedian 2.7x 6.9xmedian 2.7x 9.3xmedian 2.7x
EV/EBITDA now vs peer median 17.7xmedian 18.4x 25.7xmedian 18.4x 33.4xmedian 18.4x
P/FCF now vs peer median 11.2xmedian 25.4x 29.6xmedian 25.4x 37.1xmedian 25.4x
P/B now vs peer median 3.1xmedian 2.5x 10.0xmedian 2.5x 5.3xmedian 2.5x
PEG now vs peer median 11.74median 0.98 0.85median 0.98 -6.27median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsQGENILMNTECH
Revenue $2.12B $4.54B $1.23B
Gross profit $1.33B $3.08B $807.58M
Operating income $448.74M $960.00M $240.84M
Net income $384.93M $895.00M $171.97M
Free cash flow $964.47M $1.06B $308.20M
R&D $199.87M $975.00M $96.87M
EPS (diluted) $1.76 $5.81 $1.09
Cash & equivalents $805.13M $1.29B $350.04M
Total debt $1.64B $1.79B $200.00M
Shares (diluted) 218.88M 154.00M 157.93M
Enterprise value $7.45B $24.68B $10.42B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricQGENILMNTECH
P/E 28.2x 34.9x 66.4x
P/FCF 11.2x 29.6x 37.1x
P/Operating cash flow 17.0x 25.4x 33.9x
P/S 5.1x 6.9x 9.3x
P/B 3.1x 10.0x 5.3x
P/Tangible book 3.4x 11.4x 6.1x
EV/EBITDA 17.7x 25.7x 33.4x
EV/EBIT 25.9x 33.1x 46.9x
EV/Revenue 5.5x 7.0x 9.2x
EV/FCF 12.1x 30.0x 36.6x
EV/Operating cash flow 18.3x 25.8x 33.4x
PEG (3Y EPS CAGR) 11.74 0.85 -6.27

Growth

14 metrics
MetricQGENILMNTECH
Revenue growth (1Y) 2.2% 5.8% 0.9%
Revenue CAGR (3Y) 2.7% -0.7% 2.4%
Gross profit growth (1Y) 1.7% 8.5% 1.5%
Gross profit CAGR (3Y) 2.5% 4.4% 1.4%
Operating income growth (1Y) -7.6% 23.1% 119.1%
Operating income CAGR (3Y) 3.6% 30.0% -6.9%
Net income growth (1Y) -2.8% 27.5% 120.5%
Net income CAGR (3Y) 5.0% 40.9% -11.3%
EPS growth (1Y) -7.3% 27.5% 118.3%
EPS CAGR (3Y) 2.4% 41.2% -10.6%
Operating cash flow growth (1Y) -3.4% 9.6% 34.4%
Operating cash flow CAGR (3Y) 13.7% 47.5% 9.4%
Free cash flow growth (1Y) 1.1% 5.7% 37.6%
Free cash flow CAGR (3Y) 13.5% 126.5% 12.7%

Profitability

14 metrics
MetricQGENILMNTECH
Gross margin 62.8% 67.9% 65.8%
EBITDA margin 31.0% 27.3% 27.5%
Operating margin 21.2% 21.2% 19.6%
Pretax margin 21.7% 23.3% 18.5%
Net margin 18.2% 19.7% 14.0%
FCF margin 45.6% 23.3% 25.1%
Operating cash flow margin 30.0% 27.1% 27.5%
Return on equity 11.3% 29.9% 7.7%
Return on assets 6.5% 13.3% 6.3%
Return on invested capital 7.4% 16.6% 7.8%
Return on capital employed 8.5% 17.2% 10.7%
Asset turnover 0.4x 0.7x 0.5x
Cash conversion (OCF / net income) 1.6x 1.4x 2.0x
Stock comp / revenue 2.0% 5.9% 1.6%

Financial Health

11 metrics
MetricQGENILMNTECH
Debt / assets 27.6% 26.3% 7.6%
Debt / equity 0.5x 0.6x 0.1x
Net debt / EBITDA 1.2x 0.4x -0.4x
Debt / FCF 1.7x 1.7x 0.6x
Liabilities / assets 41.5% 53.8% 17.9%
Equity / assets 58.5% 46.2% 82.1%
Interest coverage 10.8x 9.8x 27.2x
Current ratio 2.6x 2.6x 2.3x
Quick ratio 1.9x 1.8x 1.5x
Cash ratio 1.3x 1.2x 1.0x
Altman Z-score 4.14 6.62 16.15

Shareholder Returns

7 metrics
MetricQGENILMNTECH
Dividend yield 5.3% – 0.5%
Net buyback yield 0.6% 1.2% -0.5%
Shareholder yield 5.9% 1.2% 0.1%
Payout ratio (earnings) – – 29.1%
Payout ratio (FCF) – – 16.2%
Dividend growth (1Y) – – -0.2%
Dividend CAGR (3Y) – – -0.2%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusQGENILMNTECH
Forward P/E 21.2xFY2026 40.9xFY2026 33.4xFY2027
EPS, next fiscal year $2.35FY2026 $5.06FY2026 $2.18FY2027
EPS growth, next FY -1.3%FY2026 +4.5%FY2026 +13.0%FY2027
EPS growth, the year after +17.9% +25.1% +3.2%
Revenue, next fiscal year $2.25BFY2026 $4.53BFY2026 $1.19BFY2027
Revenue growth, next FY +7.8%FY2026 +4.4%FY2026 -2.1%FY2027
Revenue growth, the year after -2.8% +12.6% +13.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersQGENILMNTECH
Held by institutions 67.3% 100.0% 100.0%
Institutions holding 338 935 599
Change in shares held, QoQ +16.5% +0.0% -0.6%
Institutions buying 216 464 293
Institutions selling 86 331 241
Buyers to sellers 2.51 1.40 1.22

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

QGENILMNTECH
QGEN 1.00 0.36 0.29
ILMN 0.36 1.00 0.20
TECH 0.29 0.20 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, QGEN, ILMN and TECH?

Illumina (ILMN) is the largest by market capitalisation: Qiagen (QGEN) $10.82B, Illumina (ILMN) $29.98B, Bio-Techne (TECH) $11.41B.

Which stock is cheaper, QGEN, ILMN and TECH?

Qiagen (QGEN) trades on the lowest price-to-earnings ratio (Qiagen (QGEN) 28.1x, Illumina (ILMN) 33.5x, Bio-Techne (TECH) 66.4x). On next year's consensus earnings, Qiagen (QGEN) is cheapest (Qiagen (QGEN) 21.2x, Illumina (ILMN) 40.9x, Bio-Techne (TECH) 33.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Illumina (ILMN) grew revenue fastest over the trailing twelve months: Qiagen (QGEN) +2.2%, Illumina (ILMN) +5.8%, Bio-Techne (TECH) +0.9%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Qiagen (QGEN) 18.2%, Illumina (ILMN) 19.7%, Bio-Techne (TECH) 14.0%). On return on invested capital, Illumina (ILMN) leads (Qiagen (QGEN) 7.4%, Illumina (ILMN) 16.6%, Bio-Techne (TECH) 7.8%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Qiagen (QGEN) +6.2%, Illumina (ILMN) +72.6%, Bio-Techne (TECH) +19.8%. Over five years, Qiagen (QGEN) compounded fastest (Qiagen (QGEN) -3.6%/yr, Illumina (ILMN) -11.1%/yr, Bio-Techne (TECH) -10.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Qiagen (QGEN) 0.00%, Illumina (ILMN) 0.00%, Bio-Techne (TECH) 0.00%. Qiagen (QGEN) and Illumina (ILMN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Qiagen (QGEN) has been the steadiest (Qiagen (QGEN) 35.2%, Illumina (ILMN) 51.1%, Bio-Techne (TECH) 42.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, QGEN, ILMN and TECH?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Illumina (ILMN) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.